IN2014MN02359A - - Google Patents
Download PDFInfo
- Publication number
- IN2014MN02359A IN2014MN02359A IN2359MUN2014A IN2014MN02359A IN 2014MN02359 A IN2014MN02359 A IN 2014MN02359A IN 2359MUN2014 A IN2359MUN2014 A IN 2359MUN2014A IN 2014MN02359 A IN2014MN02359 A IN 2014MN02359A
- Authority
- IN
- India
- Prior art keywords
- composition
- common cold
- blanose
- dipalmitoylphosphatidylcholine
- dppc
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/17—Immunomodulatory nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Otolaryngology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Pulmonology (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12166595 | 2012-05-03 | ||
| PCT/EP2013/059079 WO2013164380A1 (fr) | 2012-05-03 | 2013-05-02 | Formulations d'acide polyinosinique-polycytidylique (poly (i:c)) pour le traitement d'infections du tractus respiratoire supérieur |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014MN02359A true IN2014MN02359A (fr) | 2015-08-14 |
Family
ID=48430695
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN2359MUN2014 IN2014MN02359A (fr) | 2012-05-03 | 2013-05-02 |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US9682096B2 (fr) |
| EP (1) | EP2846767B1 (fr) |
| JP (1) | JP6349304B2 (fr) |
| KR (1) | KR102240042B1 (fr) |
| CN (1) | CN104394846B (fr) |
| AU (1) | AU2013255885C1 (fr) |
| BR (1) | BR112014026957A8 (fr) |
| CA (1) | CA2866230C (fr) |
| CL (1) | CL2014002929A1 (fr) |
| CO (1) | CO7101247A2 (fr) |
| ES (1) | ES2911116T3 (fr) |
| HK (1) | HK1203390A1 (fr) |
| IN (1) | IN2014MN02359A (fr) |
| MX (1) | MX2014013256A (fr) |
| NZ (1) | NZ630040A (fr) |
| RU (1) | RU2650636C2 (fr) |
| SG (2) | SG11201406208QA (fr) |
| WO (1) | WO2013164380A1 (fr) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9682096B2 (en) | 2012-05-02 | 2017-06-20 | Janssen R & D Ireland | Polyinosinic-polycytidylic acid (poly (I:C)) formulations for the treatment of upper respiratory tract infections |
| RU2016117398A (ru) * | 2013-11-06 | 2017-12-11 | Янссен Сайенсиз Айрлэнд Юси | Композиции полиинозиновой-полицитидиловой кислоты (поли (и:ц)) для лечения инфекций верхних дыхательных путей |
| GB201415381D0 (en) * | 2014-08-29 | 2014-10-15 | Algipharma As | Inhalable powder formulations of alginate oligomers |
| RU2017142710A (ru) * | 2015-05-11 | 2019-06-11 | Янссен Сайенсиз Айрлэнд Юси | Состав полиинозиновой-полицитидиловой кислоты (поли-(i:с)) на основе горохового крахмала для профилактики и/или лечения инфекций верхних дыхательных путей |
| CN107920993B (zh) | 2015-11-17 | 2020-11-20 | 拜昂科技医疗公司 | 包含含有双链聚核糖核苷酸与聚亚烷基亚胺的复合物的粒子的医药组合物 |
| EP3383369A4 (fr) * | 2015-11-30 | 2019-06-12 | Otic Pharma Inc. | Compositions et procédés de traitement et de prophylaxie otologique |
| TW201825102A (zh) | 2016-11-16 | 2018-07-16 | 愛爾蘭商健生科學愛爾蘭無限公司 | 用於預防上呼吸道感染之聚肌苷酸及聚胞苷酸之調配物 |
| AU2017414660A1 (en) | 2017-05-17 | 2020-01-02 | Highlight Therapeutics, S.L. | Novel pharmaceutical composition comprising particles comprising a complex of a double-stranded polyribonucleotide and a polyalkyleneimine |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8723846D0 (en) | 1987-10-10 | 1987-11-11 | Danbiosyst Ltd | Bioadhesive microsphere drug delivery system |
| US5707644A (en) * | 1989-11-04 | 1998-01-13 | Danbiosyst Uk Limited | Small particle compositions for intranasal drug delivery |
| EP0535937B2 (fr) | 1991-10-01 | 2008-05-21 | Takeda Chemical Industries, Ltd. | Préparation à base de microparticules à libération prolongée et production de celle-ci |
| GB9606188D0 (en) * | 1996-03-23 | 1996-05-29 | Danbiosyst Uk | Pollysaccharide microspheres for the pulmonary delivery of drugs |
| AR012448A1 (es) | 1997-04-18 | 2000-10-18 | Ipsen Pharma Biotech | Composicion en forma de microcapsulas o de implantes que comprende un excipiente biodegradable, polimero o co-polimero, o una mezcla de talesexcipientes, y una sustancia activa o una mezcla de sustancias activas, procedimiento para la preparacion de una sustancia soluble en agua de elevada |
| CA2203843C (fr) | 1997-04-28 | 2013-07-23 | Her Majesty The Queen, In Right Of Canada, As Represented By The Ministe R Of National Defence | Poly iclc encapsule dans des liposomes |
| MA25590A1 (fr) * | 1998-09-14 | 2002-12-31 | Inhale Therapeutic Syst | Agent actif de delivraison de poudre seche |
| CA2424892A1 (fr) * | 2000-10-06 | 2002-04-11 | Jagotec Ag | Microparticules biodegradables pour administration a liberation controlee, avec amidon a base d'amylopectine purifie de faible poids moleculaire |
| US20040248837A1 (en) | 2002-11-01 | 2004-12-09 | Eyal Raz | Methods of treating pulmonary fibrotic disorders |
| US7638138B2 (en) | 2003-02-21 | 2009-12-29 | Translational Research, Ltd. | Compositions for nasal administration of pharmaceuticals |
| US20070219149A1 (en) | 2003-08-11 | 2007-09-20 | The Research Foundation For Microbial Diseases Of Osaka University | Novel Vaccine Containing Adjuvant Capable Of Inducing Mucosal Immunity |
| EP1697511A4 (fr) | 2003-12-11 | 2007-11-21 | Vaxdesign Corp | Compositions d'immunotherapie, methodes de preparation et d'utilisation de ces dernieres |
| CN101229378A (zh) | 2005-05-05 | 2008-07-30 | 国家淀粉及化学投资控股公司 | 用于送递活性剂的组合物 |
| AU2005332599B2 (en) | 2005-06-08 | 2012-02-16 | Yisheng Biopharma (Singapore) Pte. Ltd. | Polyinosinic acid-polycytidylic acid-based adjuvant |
| US20070166239A1 (en) * | 2006-01-13 | 2007-07-19 | Haixiang Lin | Mucosal immunogenic substances comprising a polyinosinic acid - polycytidilic acid based adjuvant |
| GB0607534D0 (en) | 2006-04-13 | 2006-05-24 | Univ London Pharmacy | Colonic drug delivery formulation |
| PL2046740T3 (pl) | 2006-07-22 | 2012-10-31 | Oxagen Ltd | Związki o aktywności antagonisty CRTH2 |
| CL2007002218A1 (es) | 2006-08-03 | 2008-03-14 | Celgene Corp Soc Organizada Ba | Uso de 3-(4-amino-1-oxo-1,3-dihidro-isoindol-2-il)-piperidina 2,6-diona para la preparacion de un medicamento util para el tratamiento de linfoma de celula de capa. |
| AR067997A1 (es) | 2007-08-24 | 2009-10-28 | Novartis Ag | Compuestos organicos |
| JP2009209086A (ja) * | 2008-03-04 | 2009-09-17 | Masami Moriyama | 粘膜投与型ワクチン |
| UA90013C2 (ru) * | 2008-03-19 | 2010-03-25 | Давид Анатолійович Нога | Фармацевтическая композиция, содержащая инсулин, и способ его получения |
| EP2116602A1 (fr) | 2008-05-07 | 2009-11-11 | Institut Gustave Roussy | Combinaison de produits pour traiter le cancer |
| JP2012511519A (ja) * | 2008-12-10 | 2012-05-24 | アンフイ ジョンレン テクノロジー コーポレイション，リミテッド | 制御放出組成物 |
| CN101491503A (zh) | 2008-12-17 | 2009-07-29 | 天津瑞普生物技术股份有限公司 | 一种用于宠物的聚肌胞滴丸及其制备方法 |
| PT3098239T (pt) | 2008-12-22 | 2020-01-15 | Targimmune Therapeutics Ag | Vetor de rna de cadeia dupla dirigido ao egfr para o tratamento sistémico de cancro |
| CN101757018A (zh) | 2008-12-24 | 2010-06-30 | 天津瑞普生物技术股份有限公司 | 一种用于畜禽的聚肌胞干粉及其制备方法 |
| JP5762307B2 (ja) | 2009-03-31 | 2015-08-12 | 国立感染症研究所長 | 経鼻投与用ワクチンを用いるインフルエンザの予防方法 |
| EP2598145A1 (fr) | 2010-07-28 | 2013-06-05 | Boehringer Ingelheim International GmbH | Composition pharmaceutique pour le traitement de maladies respiratoires et inflammatoires |
| US8431155B1 (en) | 2012-04-30 | 2013-04-30 | Veroscience Llc | Bromocriptine formulations |
| US9682096B2 (en) | 2012-05-02 | 2017-06-20 | Janssen R & D Ireland | Polyinosinic-polycytidylic acid (poly (I:C)) formulations for the treatment of upper respiratory tract infections |
| RU2016117398A (ru) | 2013-11-06 | 2017-12-11 | Янссен Сайенсиз Айрлэнд Юси | Композиции полиинозиновой-полицитидиловой кислоты (поли (и:ц)) для лечения инфекций верхних дыхательных путей |
-
2013
- 2013-05-02 US US14/398,573 patent/US9682096B2/en active Active
- 2013-05-02 WO PCT/EP2013/059079 patent/WO2013164380A1/fr active Application Filing
- 2013-05-02 IN IN2359MUN2014 patent/IN2014MN02359A/en unknown
- 2013-05-02 RU RU2014148544A patent/RU2650636C2/ru active
- 2013-05-02 JP JP2015509432A patent/JP6349304B2/ja active Active
- 2013-05-02 AU AU2013255885A patent/AU2013255885C1/en active Active
- 2013-05-02 KR KR1020147028656A patent/KR102240042B1/ko active IP Right Grant
- 2013-05-02 EP EP13722334.3A patent/EP2846767B1/fr active Active
- 2013-05-02 ES ES13722334T patent/ES2911116T3/es active Active
- 2013-05-02 CN CN201380023084.4A patent/CN104394846B/zh active Active
- 2013-05-02 MX MX2014013256A patent/MX2014013256A/es unknown
- 2013-05-02 NZ NZ630040A patent/NZ630040A/en unknown
- 2013-05-02 SG SG11201406208QA patent/SG11201406208QA/en unknown
- 2013-05-02 CA CA2866230A patent/CA2866230C/fr active Active
- 2013-05-02 SG SG10201607288VA patent/SG10201607288VA/en unknown
- 2013-05-02 BR BR112014026957A patent/BR112014026957A8/pt not_active Application Discontinuation
-
2014
- 2014-10-15 CO CO14228077A patent/CO7101247A2/es unknown
- 2014-10-29 CL CL2014002929A patent/CL2014002929A1/es unknown
-
2015
- 2015-04-27 HK HK15104025.4A patent/HK1203390A1/xx unknown
-
2016
- 2016-06-13 US US15/180,603 patent/US9987300B2/en active Active
-
2018
- 2018-05-07 US US15/972,840 patent/US10485816B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| BR112014026957A2 (pt) | 2017-06-27 |
| MX2014013256A (es) | 2015-01-16 |
| US10485816B2 (en) | 2019-11-26 |
| AU2013255885A1 (en) | 2014-09-25 |
| WO2013164380A1 (fr) | 2013-11-07 |
| JP2015515968A (ja) | 2015-06-04 |
| HK1203390A1 (en) | 2015-10-30 |
| CA2866230A1 (fr) | 2013-11-07 |
| RU2650636C2 (ru) | 2018-04-16 |
| CN104394846B (zh) | 2018-10-19 |
| CA2866230C (fr) | 2020-08-18 |
| BR112014026957A8 (pt) | 2018-01-16 |
| US9987300B2 (en) | 2018-06-05 |
| KR20150008855A (ko) | 2015-01-23 |
| CL2014002929A1 (es) | 2015-01-16 |
| SG10201607288VA (en) | 2016-10-28 |
| NZ630040A (en) | 2016-10-28 |
| SG11201406208QA (en) | 2014-11-27 |
| US20150140042A1 (en) | 2015-05-21 |
| US20180325939A1 (en) | 2018-11-15 |
| CO7101247A2 (es) | 2014-10-31 |
| KR102240042B1 (ko) | 2021-04-14 |
| EP2846767A1 (fr) | 2015-03-18 |
| CN104394846A (zh) | 2015-03-04 |
| RU2014148544A (ru) | 2016-06-27 |
| US20160296551A1 (en) | 2016-10-13 |
| US9682096B2 (en) | 2017-06-20 |
| EP2846767B1 (fr) | 2022-01-26 |
| AU2013255885C1 (en) | 2018-04-26 |
| AU2013255885B2 (en) | 2017-10-05 |
| ES2911116T3 (es) | 2022-05-17 |
| JP6349304B2 (ja) | 2018-06-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014MN02359A (fr) | ||
| PH12019502269A1 (en) | Quinazoline derivatives for the treatment of viral infections and further diseases | |
| PH12015500274B1 (en) | Alkylpyrimidine derivatives for the treatment of viral infections and further diseases | |
| MX2013006040A (es) | Antagonistas del receptor de acido lisofosfatidico y su uso en el tratamiento de fibrosis. | |
| MX2015006234A (es) | Uso de akkermansia para tratar trastornos metabolicos. | |
| PH12014501738A1 (en) | Piperidino-pyrimidine derivatives for the treatment of viral infections | |
| PH12015500713A1 (en) | Acylaminopyrimidine derivatives for the treatment of viral infections and further diseases | |
| ZA201309264B (en) | Controlled release nasal testosterone gels,methods and pre-filled multi-dose applicator systems for pernasal administration | |
| MX350589B (es) | Copolimeros funcionales pla-peg, las nanoparticulas de los mismos, su preparacion y su uso para la administracion dirigida de farmacos e imagenologia. | |
| TN2014000345A1 (en) | Pharmaceutical preparation containing an antivirally active dihydroquinazoline derivative | |
| IN2015DN03219A (fr) | ||
| WO2014184576A3 (fr) | Administration de substances médicamenteuses | |
| MX2012014521A (es) | Uso de levocetirizina y montelukast en el tratamiento de influenza, resfriado comun e inflamacion. | |
| MX2016005883A (es) | Formulaciones de acido poliinosinico-policitidilico (poli (i:c))para el tratamiento de infecciones del tracto respiratorio superior. | |
| MX365688B (es) | Sistemas de administracion de farmaco y metodos para el tratamiento del cancer de vejiga que comprenden oxaliplatino. | |
| WO2014007772A3 (fr) | Compositions d'inhalation contenant du glucose anhydre | |
| BR112015001619A2 (pt) | manosídeos multiméricos, um processo para a preparação dos mesmos e as suas utilizações como um medicamento | |
| MX2015011775A (es) | Uso de levocetirizina y montelukast en el tratamiento de anafilaxis. | |
| MX2015000485A (es) | Tratamiento de esclerosis multiple con una combinacion de laquinimod y fampridina. | |
| BR112014021497A2 (pt) | sistema de entrega de fármaco baseado em jcv-vlp | |
| EP2886112A4 (fr) | Composition contenant comme principe actif de la s-allyl-l-cystéine et destinée à prévenir ou à traiter des maladies oculaires, et formulation pharmaceutique contenant cette composition | |
| WO2013038200A3 (fr) | Troubles neurodéveloppementaux | |
| EP2814498A4 (fr) | Compositions d'oligonucléotide riche en guanosine (gro), procédés et utilisations pour traiter une infection par le virus respiratoire syncytial | |
| GB201204632D0 (en) | Delivery system | |
| Ward et al. | Use of intravenous propofol in the treatment of migraine headache. |